Latest

monoclonal antibodies

·May 12, 2026·7 min read

Slowing Parkinson’s by Blocking a Key Protein

A new study found that GPNMB, released by the brain's immune cells, accelerates the spread of toxic alpha-synuclein. By using monoclonal antibodies to block GPNMB, the team successfully interrupted the cycle of neurodegeneration in preclinical models. This discovery provides a new therapeutic target that could finally slow the progression of Parkinson’s at its earliest stages.

Featured Neurology Neuroscience

·April 16, 2024·4 min read

Monoclonal Antibody Slows Rapid Motor Decline in Parkinson’s

Prasinezumab, a monoclonal antibody targeting alpha-synuclein aggregation, shows promise in slowing motor deterioration in rapidly progressing Parkinson's disease (PD), according to an exploratory analysis from the phase 2 PASADENA clinical trial. While there are currently no disease-modifying treatments for PD, prasinezumab offers a potential breakthrough by specifically binding to aggregated alpha-synuclein, a key driver of PD pathology.

Featured Genetics Neuroscience Open Neuroscience Articles

·November 9, 2022·4 min read

Monoclonal Antibodies Preserve Stem Cells in Mouse Brains

Using monoclonal antibodies instead of conventional immunosuppressant drugs preserves stem cells in mouse brains.

This is a cartoon of a woman rubbing her back in pain

Featured Neurology Neuroscience Neuroscience Videos Pain

·September 25, 2022·4 min read

Could Monoclonal Antibodies Replace Opioids for Chronic Pain?

Researchers are developing a monthly monoclonal antibody therapy for the treatment and management of chronic pain. The hope is this new therapy can replace opioids for pain management.